Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

What happened: Astellas and Audax Biosciences entered an exclusive option and license agreement for DAX-044, an investigational IL-12 antibody-cytokine fusion for immuno-oncology. Why it matters: Astellas said the deal strengthens its immuno-oncology pipeline and complements its targeted immunotherapy portfolio. Audax said the partnership will expedite planned Phase 1 evaluation of DAX-044 for patients with solid tumors.

Astellas and Audax Biosciences entered an exclusive option and license agreement for DAX-044, an investigational IL-12 antibody-cytokine fusion for immuno-oncology.

Astellas said the deal strengthens its immuno-oncology pipeline and complements its targeted immunotherapy portfolio. Audax said the partnership will expedite planned Phase 1 evaluation of DAX-044 for patients with solid tumors.